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Abstract
Objective
To summarise evidence describing the cost-effectiveness of population-based interventions
targeting sodium reduction.
Methods
A systematic search of published and grey literature databases and websites was con-
ducted using specified key words. Characteristics of identified economic evaluations were
recorded, and included studies were appraised for reporting quality using the Consolidated
Health Economic Evaluation Reporting Standards (CHEERS) checklist.
Results
Twenty studies met the study inclusion criteria and received a full paper review. Fourteen
studies were identified as full economic evaluations in that they included both costs and ben-
efits associated with an intervention measured against a comparator. Most studies were
modelling exercises based on scenarios for achieving salt reduction and assumed effects
on health outcomes. All 14 studies concluded that their specified intervention(s) targeting
reductions in population sodium consumption were cost-effective, and in the majority of
cases, were cost saving. Just over half the studies (8/14) were assessed as being of ‘excel-
lent’ reporting quality, five studies fell into the ‘very good’ quality category and one into the
‘good’ category. All of the identified evaluations were based on modelling, whereby inputs
for all the key parameters including the effect size were either drawn from published data-
sets, existing literature or based on expert advice.
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Conclusion
Despite a clear increase in evaluations of salt reduction programs in recent years, this
review identified relatively few economic evaluations of population salt reduction interven-
tions. None of the studies were based on actual implementation of intervention(s) and the
associated collection of new empirical data. The studies universally showed that population-
based salt reduction strategies are likely to be cost effective or cost saving. However, given
the reliance on modelling, there is a need for the effectiveness of new interventions to be
evaluated in the field using strong study designs and parallel economic evaluations.
Background
As the non-communicable diseases (NCD) crisis becomes an urgent race against time [1], it is
critical to understand the effectiveness of interventions designed to lower the risk factors asso-
ciated with cardiovascular disease (CVD), which is now the leading cause of deaths globally
[2]. Recent data highlight blood pressure as a leading risk to health [3], and one of the main
causes of elevated blood pressure is excess dietary sodium intake [4,5].
Excess dietary sodium intake is likely to be responsible for about half of the disease burden
ascribed to high blood pressure [6] making sodium a major contributor to mortality from
CVD [7]. As a result, interventions targeting the reduction of population-wide sodium intake
are increasingly being prioritised [8]. New Guidelines issued by the WHO in 2012 recommend
that adults should consume less than 2000mg of sodium or 5 grams of salt per day [9]. This is
significantly lower than the average intake in many countries such Samoa which averages 7.09
grams [10], Australia around 8 grams [11] and the United States 8.5 grams [12] per day. Recent
estimations from the Global Burden of Disease study suggest that global salt intake is around
10grams/day [13]. For many countries, reaching the sodium guideline of 5 grams per day
would require a 50% reduction in daily salt intake from current levels.
There is compelling evidence that a reduction in sodium intake significantly reduces resting
systolic blood pressure [14] and is therefore likely to reduce the risk of a CVD event [15]. A
high intake of sodium increases blood pressure levels with age, greatly increasing the risk of
cardiovascular disease and contributing to nearly half the disease burden attributed to high
blood pressure [16]. Evidence from epidemiology and from high quality analysis of random-
ized clinical trials shows a direct relationship between blood pressure and cardiovascular dis-
eases [17–21]. There is also increasing evidence that population interventions to reduce salt
are effective in reducing blood pressure [18,22]. Further evidence from a meta-analysis of ran-
domized salt reduction trials estimated that a reduction in salt intake of 6 g/day would reduce
the prevalence of strokes by 24% and coronary heart disease by 18% [15].
A range of interventions has been developed and implemented in efforts to reduce sodium
consumption with the choice of salt reduction strategy depending upon the source of sodium
in the diet [23]. In developed countries, the majority of sodium comes from processed foods
such as bread, processed meat, cheese and fast food, whereas in developing countries, a greater
proportion typically derives from salt added during cooking or at the table [15]. The main
interventions for sodium reduction include product reformulation (both voluntary and man-
datory), health promotion campaigns, mandatory labeling of salt content on pre-packaged
food, and taxation or other incentives to encourage the food industry to moderate the level
of salt in processed foods [23]. Sodium reduction interventions are commonly shown to be
highly effective in reducing sodium intake at a population level. A recent evaluation of the salt
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reduction initiative in the United Kingdom of Great Britain and the Northern Ireland demon-
strated a significant reduction in average intakes from 9.5 grams per day in 2000 to 8.1 grams
per day in 2011 [24]. The initiatives consisted of an awareness campaign shown on TV through
a series of adverts along with a series of partnerships with institutions running programs such
as peer education and social cooking classes. The strategy also involved working with the food
industry to encourage product reformulation.
Interventions that reduce sodium intake have been shown to be one of the most cost-effec-
tive measures to improve public health worldwide [25]. These interventions generally target
whole populations and seek to reduce exposure to dietary sodium [26]. It is estimated that a
15% reduction in population-wide sodium consumption would avert up to 85 million deaths
in 23 high-burden countries over 10 years [6].
Whilst numerous studies explore the effectiveness of sodium reduction interventions on
salt intake through urine collections, effect on blood pressure or cardiovascular disease out-
comes [14,19,27], decision makers are also interested in which interventions deliver value-for-
money in the context of limited health care resources. Economic evaluations are extremely
valuable in decision making as they enable the best course of action to be identified based on
the evidence available by systematically analyzing the costs and benefits associated with an
intervention and assessing its value for money [28]. Whilst there is broad agreement that
sodium reduction strategies are cost-effective, there are many different evaluation approaches
and perspectives used, and the completed evaluations vary in quality.
The objective of this paper was to conduct a systematic review of the literature to identify
economic evaluation studies of interventions targeting sodium reduction and summarise evi-
dence about their cost-effectiveness.
Important definitions
A table of important definitions has been compiled below in Table 1, defining important terms
used throughout this paper.
Methods
Search strategy
Databases searched. Literature on economic evaluations of sodium reduction interven-
tions published between 1980 and 2015 were identified from a search of journal databases,
grey literature and other articles identified by experts in the field. During January 2015, the
published literature was searched using the following search engines which comprise the main
health databases: Pubmed, Embase, EBSCO Host, OVID and Google Scholar. This review
explores the existing literature on both economic evaluations of sodium reduction interven-
tions actually implemented in the field and involving new empirical data collection as well as
desk-based modelled simulation studies.
A search of grey literature was also undertaken using the same search terms in order to find
information that may only have been published in government reports or discussion papers.
The search was undertaken using Google, Open Grey, the World Health Organization data-
base and website and the World Bank website. The reference lists of extracted articles were
also searched for any additional studies.
Search terms. Each database was searched using the following key words: “Economic
Evaluat”, “Cost Effect”, “Cost Benefit”, “Cost Utility”, “Cost Analyses” and “Intervention”.
Each search term was combined with the key words “Sodium OR Salt” and “Reduc”.
Study inclusion criteria. To be included, a study had to comply with all of the following
criteria:
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1. Be an intervention or simulation study that targeted the reduction of sodium intake at a
population level (i.e. targeting populations rather than individuals). Both prospective and
retrospective studies were included.
2. Presented the findings of full economic evaluations which explore both costs and benefits
in relation to a comparator. A full economic evaluation was defined as the comparative
analysis of alternative courses of action in terms of both costs (resource use) and conse-
quences (outcomes, effects) [30]. Full economic evaluations include studies utilising CBA,
CEA or CUA. Partial economic analyses, which focused solely on costs and resource used,
or which did not entail a comparator, were excluded.
3. Published from 1980 to December 2015.
4. Reported in English.
The systematic review was conducted by SH following the Preferred Reporting Items for
Systematic Reviews and Meta-Analyses (PRISMA) guidelines [32]. The results were identified
by title, then screened by abstract, followed by a full text assessment for eligibility.
Analyses. Key characteristics of the economic evaluation of each of the identified sodium
reduction studies were extracted into a spreadsheet including the economic evaluation study
design, year and country of study, setting, sample size, time horizon, study perspective, study
comparator, intervention(s) analyzed, the methods or models used to conduct the economic
evaluation, costs included, the primary outcome measure and the main results and conclusions
of the study.
The reporting quality of the identified studies was measured against the Consolidated
Health Economic Evaluation Reporting Standards (CHEERS) checklist for assessing economic
Table 1. Important definitions.
Term Definition
Sodium A mineral, and one of the chemical elements found in salt. Salt
(sodium chloride) is made up of 40% sodium and 60% chloride. One
teaspoon of table salt contains 2,325 mg of sodium [29].
Cost-effectiveness analysis
(CEA)
An evaluation in which the effects of an intervention (and its comparators)
are measured in identical units of outcome (e.g. mortality, myocardial
infarctions) and alternative interventions are compared in terms of ‘cost
per unit of effect’ [30].
Cost-utility analysis (CUA) When alternative interventions produce different levels of effect in terms
of both quantity and quality of life (or different effects), the effects may be
expressed in utilities. Utilities are measures which comprise both length
of life and subjective levels of well-being. The best known utility measure
is the quality-adjusted life year, or QALY. Alternative interventions are
compared in terms of cost per unit of utility gained (e.g. cost per QALY)
[30].
Cost-benefit analysis (CBA) When both resource inputs and effects of alternative interventions are
expressed in monetary units, so that they compare directly and across
programs within the healthcare system, or with programs outside health
care (e.g. healthcare intervention vs. criminal justice intervention) [30].
Incremental cost-effectiveness
ratio (ICER)
Entails determination of the incremental cost of an additional unit of
health benefit thereby enabling different interventions to be ranked in
terms of their economic credentials. The ICER is calculated by difference
in cost between two possible interventions, divided by the difference in
their effect [30].
Economic Perspective A viewpoint that envisions individuals and institutions making rational
decisions by comparing the marginal benefits and marginal costs
associated with their actions [31].
https://doi.org/10.1371/journal.pone.0173600.t001
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evaluations [33,34]. The 24 item checklist is designed to improve reporting of economic evalu-
ations. Each of the included articles were assessed for reporting quality independently by two
reviewers (SH, MM) against the criteria to calculate a score out of 24 (or the number of appli-
cable items). Each item on the checklist was assigned one point, but half points were awarded
where the article partially filled the criteria (e.g. provided no explanation for choice of discount
rate or choice of model). The two reviewers (SH and MM) discussed any differences in criteria
ratings in order to reach consensus. A percentage score for each study was then calculated.
In the absence of a broadly accepted method for reporting quality appraisal, categories were
set based on methods from other literature [35–37]—a study was deemed to be of excellent
reporting quality if it scored 85% or higher, 70-<85% very good quality, 55-<70% good quality
and studies scoring below 55% were classified as poor quality.
Results
Search results
From the initial search, a total of 3647 potentially relevant publications were identified.
Some 924 duplicates were removed. Of the remaining 2723 titles, 2639 were found to be not
relevant based on the title key words. A review of the abstracts of the remaining 84 articles
identified a total of 25 potentially relevant studies. After a partial review of the full article, a fur-
ther 10 papers were excluded as they did not meet the selection criteria (seven did not present
findings of an economic evaluation, two were not available in English, and one was a confer-
ence abstract).
In addition to the fifteen articles identified from the database search, an additional five arti-
cles were identified through either the grey literature search or referral from persons working
in the field. So in total, 20 studies were identified that met the study inclusion criteria and were
subjected to a full paper review [22,38–56].
Five of the twenty studies [22,38–41], whilst purporting to be cost-effectiveness analyses,
did not actually specify an intervention. Another [56] was excluded as it was a protocol. Four-
teen articles [42–55] were full economic evaluations in that they included both costs and bene-
fits associated with an intervention measured against a comparator. A flow diagram of the
selection process, according to the PRISMA Guidelines is shown below in Fig 1 [32].
The majority of studies (11/14) have been published in the past five years (2010 or later),
with the other three studies being in the decade 2000–2009. This is a reflection of both the rela-
tive newness of attention being focused on sodium reduction interventions as a measure to
curb hypertension, and of the infancy of the exposure of such interventions to economic
evaluation.
The 14 papers outlined in Table 2 [42–55] were full economic evaluations in that they
included both costs and benefits associated with a defined intervention measured against a
comparator. The characteristics of these papers are summarised in Table 3 and explained in
the following section.
Target settings and populations. The identified articles contained economic evaluations
of interventions from a wide range of countries. Four were from low and middle income coun-
tries or regions [43,44,52,55], and 10 were from high income countries as classified by the
World Bank [57]. The former group included studies from Vietnam, Syria and the Middle
East (four countries in one study) and South-East Asia & Sub Saharan Africa. The latter group
comprised four studies from the USA, England, Australia and Argentina, and Norway. The
target group for the majority of studies was a national population; however one study targeted
the population of a single city (Buenos Aries), whilst three were regional studies targeting mul-
tiple countries.
A review of economic evaluations of sodium reduction interventions
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Seven of the 14 studies evaluated interventions which targeted the whole population of
either a specific country [46,52], multiple countries [44,53,54], several regions [47,55], or a city
[51]. Mason et al. [44] evaluated the intervention separately for the population of four Eastern
Mediterranean countries (Palestine, Syria, Tunisia and Turkey), whilst Webb [53] modelled
results separately for 187 different countries worldwide, Murray et al [47] for 14 epidemiologi-
cal sub regions and Ortegon et al [55] for the populations of sub-Saharan Africa and South
East Asia. Rubinstein 2009 focused on the city population of Buenos Aires [51]. Cobiac et al
[46] and Ha et al [52] evaluated intervention for the populations of Australia and Vietnam
respectively.
Of the 14 studies, the interventions were targeted at adults of varying age ranges. Four tar-
geted young to middle age adults (35 or 40 years and over) [42,48–50], although the latter
study was confined to adults (35–85 years) who had never experienced a CVD event. Two
studies lowered the youngest age to between late adolescence or early adult years (between 16–
25 years and upwards) [43,45]. There were no studies focusing exclusively on children.
Study perspective. The economic perspective of a study is important in determining the
costs and benefits included. Six of the studies [42,44,45,47,49,52] purport to include a societal
perspective, which means that all costs and benefits are included irrespective of who incurs
them. The remaining studies reported from a health sector perspective [46,48,50,54,55], or
government perspective [51,53]. The perspective taken by Wilcox et al. [43] was not specified.
Interventions and comparator. A range of interventions aiming to reduce sodium con-
sumption were identified. These consisted of activities aiming to influence both the supply and
demand side of the food system. Supply side interventions aimed to alter the available food by
providing access to lower sodium options. The main example is product reformulation (both
voluntary and mandatory) to reduce the salt content of food. Demand side interventions
aimed to influence demand by changing people’s behavior so that they select lower sodium
Fig 1. Flow diagram of selection process, according to PRISMA Guidelines [32].
https://doi.org/10.1371/journal.pone.0173600.g001
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options. Examples included health promotion campaigns, labeling of salt content on packaged
food and taxes on salty food products.
All interventions analysed were compared to either the status quo (current practice) or a
null comparator. The latter, based on WHO-CHOICE methodology [58], entails an assump-
tion of no interventions being in place, meaning that the intervention is compared to a situa-
tion of no costs and no interventions.
Over half of the studies (8/14) evaluated multiple sodium reduction interventions [43–
47,49,52,55], while the remaining six studies evaluated only one sodium reduction strategy
[42,48,50–54]. Seven of the studies [42–46,49,53] were focused exclusively on sodium reduc-
tion strategies, whilst in the other seven studies [47,48,50–52,54,55], a broader focus on the
reduction of cardiovascular disease meant that the salt reduction interventions were evaluated
along with a range of other non-salt initiatives. As an illustration of the latter, Murray et al
2013 [47] considered three salt interventions (health education through mass media, legisla-
tion and voluntary agreements on food labelling and salt content) amongst a total of 17 popu-
lation and individual strategies to lower systolic blood pressure and cholesterol. Likewise,
Cobiac et al. 2012 [48] included the mandatory reduction of salt in the manufacture of breads,
margarines and cereals as part of a broader study of nine interventions exploring the best value
for money in the primary prevention of cardiovascular disease. Of these eight studies, three
evaluated two salt interventions [49,52,55], three had three interventions [43,44,46] and two
had four interventions [45,47].
In the case of two of the six studies evaluating one salt reduction intervention only [42,53],
the intervention was a multi-component intervention targeting sodium reduction, comprising
product reformulation with a health promotion/education component. The other four were
single component interventions [48,50,51,54].
The majority of the studies included a product reformulation strategy designed to reduce
the sodium content of processed foods. Five studies [45–47,53,55] evaluated the cost-effective-
ness of both voluntary and mandatory (regulatory) measures to restrict the salt content of pro-
cessed foods, whilst four [43,44,48,54] included mandatory reformulation and five [42,49–52]
included voluntary programs targeting the food industry. The other salt reduction initiative
common to seven of the papers was a health promotion/education program [42–45,47,52,53].
Table 3. Summary of study characteristics.
Study Characteristics Number of studies identified
Study type
CEA 0
CUA 14
CBA 0
Study perspectives
Societal 6
Health Sector or healthcare perspective 5
Government 2
Not specified 1
Comparator selected
Current practice 12
No intervention 2
Country or region income level
High income countries 10
Low and middle income countries or regions 4
https://doi.org/10.1371/journal.pone.0173600.t003
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Whilst the English study by Collins et al. [45] specified a particular health program (Change4-
Life), and Ha et al. [52] specified health education via a mass media campaign, generally little
detail was provided on the nature of the program.
Only two studies evaluated tax legislation for salt reduction. Selmer et al. [42] included
taxes on salty foods and subsidies on products with less salt as components within a multi-
pronged salt reduction program. In contrast to point-of-sale tax measures, Smith-Spangler
et al. [49] evaluated the impact of a tax imposed on sodium used in food production.
All of the studies assumed that the full effect of the intervention would be maintained over
time. This assumption seems reasonable for interventions such as product reformulation and
tax legislation however this may not always be realistic for health promotion and education
programs. Three studies [42,46,53] assumed that effects would appear gradually from the
onset of the intervention and increase to full effect. Only study [48] explicitly mentions that
the effect of the interventions is only assumed if the delivery of interventions is ongoing.
Time horizons. Economic evaluations should specify time horizons, both for the provi-
sion of the intervention itself and for tracking the associated costs/cost offsets and conse-
quences. The evaluated duration of intervention delivery should ideally reflect how the
intervention would be applied in real life. There were a range of study time lines in the identi-
fied studies; the studies generally do not justify their choice of time frame for tracking costs
and benefits. Half of the studies (7/14) had a 10 year study time line in which the costs and
consequences of the interventions were evaluated [43–45,52–54,59]. One study [42] had a 25
year timeline and one estimated annual costs and benefits [50]. The remaining five studies
measured results over 100 years or the lifetime of the target group [46–49,55]. In the small
number of studies which actually specified the intervention duration, it ranged from five to 25
years.
Study designs and models employed. All of the 14 studies entailed a cost-utility analysis
where the incremental cost-effectiveness ratios were reported as a ratio of costs against a mea-
sure of utility. Four studies [42–45] reported cost per life years gained, and two [49,54], costs
per quality-adjusted life years (QALY) gained. All of the other studies measured costs per dis-
ability-adjusted life year (DALYs) saved.
The studies employed various forms of simulation modelling to examine the impact of the
specified intervention on population health. Four studies based their analytic model on the
WHO-CHOICE methodology [47,51,52,55]—reductions in population attributable risks of
cardiovascular events resulting from an intervention were calculated, and then translated into
changes in population health using the standard multi-state model, Pop Mod. Pop Mod esti-
mates the lifetime health gains for each age and sex cohort of the given population (divided
into different health states) both with and without the intervention. Three studies [43–45]
used country specific versions of IMPACT, a comprehensive, validated coronary heart disease
(CHD) model to estimate the reduction in CHD mortality stemming from an intervention.
Other studies [42,48,49] developed purpose-built Markov models which assume that each par-
ticipant is always in one of a finite number of discrete health states and events are represented
as transitions from one state to another.
Discount rates. The majority of studies (11/14) applied a 3% discount rate to costs and
benefits, whilst Collins et al [45] and Barton et al [54] used a 3.5% rate and Selmer et al [42] a
5% rate. The choice of discount rate was expected to vary between settings and location but
most of the studies did not justify their choice of rate level.
Resource use costing. Items included in the cost measurement varied depending on
the study purpose and perspective and the nature and number of intervention(s) being evalu-
ated. Some studies such as Wilcox et al [43] and Collins et al [45], assumed a broad, societal
approach to costing, in order to facilitate the inclusion of costs to all sectors, including the
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food industry (for example, the costs of product reformulation and relabeling). Others adopted
a narrower focus and confined themselves, for instance, to costs to government [51,53] or the
health care sector [54].
Quality assessment of the studies. The reporting quality of the 14 studies was assessed
against 24 checkpoints and allocated a score of 1 for each point that was met in full (symbol-
ized as
p
), a score of 0.5 for each point that was partially met (symbolized as 6¼) and a score of
0 for each point that was not met (symbolized as X) (Table 4). The majority of studies (8/14)
[44,46,48–52,55] were found to be of excellent reporting quality (scoring 85% or higher), with
the remaining five to be of ‘very good’ quality (scoring 70–85%) [42,43,45,47,54] and one to be
of ‘good’ quality (scoring 55–70%) [53].
The two criteria which were least well addressed were the time horizon and model choice.
Whilst the time horizon for each study was generally specified, most studies omitted to provide
reasons for choice. Likewise, very few studies provided justification for their choice of eco-
nomic model. Other key areas where studies lost quality points related to study perspective
(sometimes it was not explicitly stated or related to the costs included) and health outcomes
(where their relevance was not made clear). It should be noted that the assessment of reporting
quality is not indicative of the quality of the actual study results.
Cost-effectiveness results
All of the fourteen studies concluded that their specified interventions targeting reductions in
sodium consumption were cost-effective, and in the majority of cases, were cost saving (in
other words, they resulted in health gains at a lower cost, measured against the comparator)
(Table 5). For example, Barton et al. [54] concluded that any sodium reduction initiative that
achieved even a modest population-wide reduction in any major cardiovascular risk factor
would produce a net cost saving to United Kingdom’s National Health Service.
Many studies examined the cost-effectiveness of a combination of interventions making it
sometimes difficult to ascertain the effectiveness of a single intervention. In the seven studies
[47,48,50–52,54,55] which evaluated both salt reduction strategies and other non-salt strategies
to reduce poor cardiovascular outcomes, the strategies focused on salt reduction generally rep-
resented the best ‘value-for-money’ given their low-cost and population wide impacts. For
example, Ha et al. [52] evaluated 12 population and individual level interventions to prevent
cardiovascular disease in Vietnam and found a mass media campaign to reduce salt intake as
the most cost-effective. Likewise, Cobiac et al 2012 [48] showed that mandating the more mod-
erate use of salt in breads, margarines and cereals was easily the most cost-effective strategy for
primary prevention of cardiovascular disease in Australia.
Whilst the results are generally not comparable between studies due to the heterogeneous
nature of the methods used, the studies that evaluated multiple salt interventions indicate that
some initiatives are consistently more cost-effective than others. Mandatory product reformu-
lation was found to be substantially more cost-effective than the food industry sector undertak-
ing voluntary reformulation [45–48]. The 2010 study by Cobiac et al. [46] found that making
recommended limits for salt in bread, margarine and cereal products mandatory would poten-
tially avert 18% of the disease burden arising from excessive salt consumption which was 20
times greater than the health gains achieved with the voluntary approach.
There was also evidence from two studies that multiple interventions working together are
likely to be more cost-effective than any single intervention (e.g. [43,44]. Mason et al. [44]
found that in all four Eastern Mediterranean countries targeted a comprehensive strategy of
health education, food labelling and mandatory product reformulation would produce the
greatest benefit in terms of life years gained and cost savings.
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Table 4. Quality Assessment Results against CHEERS Checklist.
Title
Identified as
economic
evaluation
Structured
abstract
Intro provides
context and a
clear study
question
Population
characteristics
Setting and
location
Study
Perspective
Comparators
described
Time
horizon
Discount
rate
Author: 1 2 3 4 5 6 7 8 9
Selmer et al
2010
X p p p p 6¼ p 6¼ X
Wilcox 2014 p 6¼ p p p X p 6¼ p
Mason et al
2014
p p p p p
6¼
p
6¼
p
Colins et al
2014
p p p p p
6¼
p
6¼
p
Cobiac et al
2010
p p p p p p p p p
Murray et al
2005
X p p p p 6¼ p 6¼ p
Cobiac et al
2012
p
6¼
p p p p p X p
Smith-
Spangler
et al 2010
p p p p p p p
6¼ 6¼
Rubinstein
2010
p p p p p p p p
6¼
Rubenstein
2009
p p p p p p p
6¼ 6¼
Ha &
Chisholm
p p p p p p p p p
Webb 2012 p X p p X X p 6¼ 6¼
Barton et al
2011
p p p p p X p 6¼ p
Ortegon
et al 2012
p p p p p p p p p
Outcomes
and
relevance
Measurement of
effectiveness
Pref based
outcomes
Costs (unit costs
and methods) or
Costs model
based studies
Currency,
date and
conversion
Model
choice
described
Model
assumptions
Analysis
methods
Parameters
of values
Author: 10 11 12 13 14 15 16 17 18
Selmer et al
2010
p p NA p p 6¼ p X p
Wilcox 2014 p p NA p p 6¼ p p 6¼
Mason et al
2014
6¼
p NA p p 6¼ p p p
Colins et al
2014
6¼
p NA p X 6¼ p p p
Cobiac et al
2010
6¼
p p p p p p p p
Murray et al
2005
p p X p p 6¼ p p X
Cobiac et al
2012
p p p p p
6¼
p p p
Smith-
Spangler
et al 2010
6¼
p p p p
6¼
p p p
Rubinstein
2010
6¼
p p p p
6¼
p p p
(Continued )
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Discussion
The economic evaluations of the identified studies indicate that interventions to reduce
sodium consumption generally represent excellent value for money; or in other words, are
either cost saving (more health gains at lower cost) or cost-effective (more health gains but at
some additional cost). Most of the interventions are low cost in terms of their implementation
costs, but produce significant long-term improvements in population health, thereby resulting
in sizeable cost savings to society by substantially decreasing the cardiovascular disease burden
and associated health care expenditure. Interventions focusing on curbing salt intake were
Table 4. (Continued)
Rubenstein
2009
p p p p p
6¼
p p p
Ha &
Chisholm
p p p p p p p p p
Webb 2012 6¼ p p p p 6¼ p p X
Barton et al
2011
6¼
p p p p
6¼
p p X
Ortegon
et al 2012
6¼
p p p p p p p p
Incremental
costs
Sensitivity of
incremental
costs or model
sensitivity
analyses
Heterogenity
explained
Findings and
limitations
Funding
source
Potential
conflict of
interest
Author: 19 20 21 22 23 24 Total %
Selmer et al
2010
X p p 6¼ 6¼ p 16.5/23 72%
Wilcox 2014 p p NA p 6¼ X 17.5/22 80%
Mason et al
2014
p p p p p p
21/23 91%
Colins et al
2014
p p p p p X 19/23 83%
Cobiac et al
2010
p p p p p p
23.5/24 98%
Murray et al
2005
p p p p
6¼
p
19/24 79%
Cobiac et al
2012
p p p p p p 22/24 92%
Smith-
Spangler
et al 2010
p p NA p p p 21/23 91%
Rubinstein
2010
p p NA p 6¼ p 21/23 91%
Rubenstein
2009
p p NA p 6¼ p 21/23 91%
Ha &
Chisholm
p p NA p 6¼ X 21.5/23 93%
Webb 2012 6¼ p p p X X 15.5/24 65%
Barton et al
2011
6¼
p p p p p
20/24 83%
Ortegon
et al 2012
p p p p p p
23.5/24 98%
https://doi.org/10.1371/journal.pone.0173600.t004
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shown to be more cost-effective in avoiding poor cardiovascular disease outcomes than other
non-salt strategies. This finding was in line with results from previous studies [60–62].
Whilst most of the 14 studies were from high income countries, there were several studies
in middle or low income countries. The majority of the studies have been published in the past
ten years. Whilst growing attention is being given to effective interventions to reduce salt con-
sumption, very few interventions to date have been subjected to economic evaluation. Also,
the interventions which have been evaluated in terms of their economic credentials are narrow
in terms of their content; most related to product reformulation, relabeling, or health promo-
tion programs, with only a couple targeting tax legislation.
A recent systematic review of salt reduction initiatives around the world identified inter-
ventions in different categories: food reformulation, consumer education, front of pack label-
ling and interventions in public institution settings and taxation [23]. This review found that
economic evaluations have been completed for all sodium reduction intervention categories
except for the ‘interventions in public institution settings’ category. There was also one study
identified [49] relating to sodium taxation. This indicates a gap in existing literature and a
need for economic evaluations of these different interventions.
None of the identified studies were based on actual implementation and evaluation of inter-
ventions. Instead the interventions were simulated using economic modelling and interven-
tion effectiveness data were drawn from external sources or the academic literature. None of
the papers made explicit mention of procedures for checking their models. Five of the studies
used an existing validated model for their analyses. Three of the studies [43–45] reported using
the existing validated IMPACT CHD model to compare their results, whilst two of the studies
[47,51] used PopMod to model their analyses. Future evidence would be strengthened by the
actual implementation of intervention trials within real-life settings. Despite this reliance on
modelling and associated assumptions, the studies evaluated are important as model-based
health economic evaluations are today widely accepted as policy-making tools that can inform
resource allocation decisions.
A key strength of this review is the systematic and comprehensive method of data collec-
tion. A comprehensive search strategy was employed encompassing both peer reviewed and
grey literature. The quality assessment of the economic evaluations undertaken as part of this
review adds strength to the conclusions since all studies were found to be of good, very good
or excellent reporting quality. The results in this review are limited to those published in
English representing a potential limitation. Another limitation is that studies identified were
not based on actual implementation of intervention(s) and the associated collection of new
empirical data. Given the result of the studies are based on modelling and assumed costs and
effectiveness, researcher bias may have influenced these findings. All studies identifies were
based on modelling where inputs were drawn from published datasets, existing literature or
Table 5. Summary of cost-effectiveness results.
Intervention type Number of studies
evaluated
Number cost-
effective
Number cost
saving
Both voluntary and mandatory
reformulation
5 3 2
Mandatory reformulation 4 1 3
Voluntary programs targeting the
food industry
5 1 4
Health promotion/education
programs
7 1 6
Tax legislation 2 0 2
https://doi.org/10.1371/journal.pone.0173600.t005
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expert advice. As the results from the study rely heavily on modelling, there is a need for the
effectiveness of new interventions to be evaluated in the field using strong study designs and
parallel economic evaluations.
Conclusions
Reducing the consumption of salt is now seen as a key priority in many strategies targeting the
prevention of cardiovascular disease but relatively few interventions designed to lower salt
intake have been rigorously evaluated. Even fewer have been examined in terms of their eco-
nomic credentials. Nevertheless, the economic evaluations identified in this field suggest that
salt lowering strategies are potentially cost effective and offer better value-for-money than
many other non-salt strategies. In addition to simulation modelling studies, there is an urgent
need for the effectiveness of salt interventions to be actually evaluated in the field using strong
study designs, and economic evaluations conducted in parallel.
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